Notice of Award of a Single-Source Cooperative Agreement To Fund the National Lung Hospital (NLH)/National Tuberculosis Program, Vietnam
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Issuing agencies
Abstract
The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces the award of approximately $1,500,000, for Year 1 of funding to the National Lung Hospital (NLH)/National Tuberculosis Program (NTP). The award will support high quality TB, multi-drug resistant TB (MDR-TB), and TB/HIV programs to strengthen and expand TB and MDR-TB quality- assured diagnostic capacity (clinical and laboratory testing); promote TB, MDR-TB, and TB/HIV prevention and integration into existing healthcare services; strengthen TB surveillance and monitoring and evaluation (M&E) and improve collaboration and coordination between TB and other programs, particularly HIV and COVID-19. Funding amounts for years 2-5 will be set at continuation.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 24 (Friday, February 4, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 24 (Friday, February 4, 2022)]
[Notices]
[Pages 6561-6562]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-02412]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Award of a Single-Source Cooperative Agreement To Fund
the National Lung Hospital (NLH)/National Tuberculosis Program, Vietnam
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), located
within the Department of Health and Human Services (HHS), announces the
award of approximately $1,500,000, for Year 1 of funding to the
National Lung Hospital (NLH)/National Tuberculosis Program (NTP). The
award will support high quality TB, multi-drug resistant TB (MDR-TB),
and TB/HIV programs to strengthen and expand TB and MDR-TB quality-
assured diagnostic capacity
[[Page 6562]]
(clinical and laboratory testing); promote TB, MDR-TB, and TB/HIV
prevention and integration into existing healthcare services;
strengthen TB surveillance and monitoring and evaluation (M&E) and
improve collaboration and coordination between TB and other programs,
particularly HIV and COVID-19. Funding amounts for years 2-5 will be
set at continuation.
DATES: The period for this award will be September 30, 2022 through
September 29, 2027.
FOR FURTHER INFORMATION CONTACT: Amy Bailey, Center for Global Health,
Centers for Disease Control and Prevention, 5th/Floor Tung Shing
Building, No 2, Ngo Quyen Street, Hoan Kiem District Hanoi, Vietnam,
Telephone: 800-232-6348, email: <a href="/cdn-cgi/l/email-protection#c5a3b0a0fd85a6a1a6eba2aab3"><span class="__cf_email__" data-cfemail="422437277a022126216c252d34">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: The single-source award will contribute to
enhancing early and universal access to high quality prevention,
diagnosis, and treatment services for TB, MDR-TB, and TB/HIV with the
goal of ending TB in Vietnam by 2030.
The NLH/NTP is in a unique position to conduct this work as it is
mandated by Vietnam Ministry of Health (MoH) with oversight and
implementation of TB prevention and control activities in Vietnam. The
NLH is the leading tertiary hospital in charge of examination and
treatment of TB and lung diseases and steering TB and lung disease
prevention and control activities throughout the country.
Summary of the Award
Recipient: National Lung Hospital (NLH)/National Tuberculosis
Program (NTP).
Purpose of the Award: The purpose of this award is to support high
quality TB, MDR-TB, and TB/HIV programs to strengthen and expand TB and
MDR-TB quality-assured diagnostic capacity (clinical and laboratory
testing); promote TB, MDR-TB, and TB/HIV prevention and integration
into existing healthcare services; strengthen TB surveillance and M&E
and improve collaboration and coordination between TB and other
programs, particularly HIV and COVID-19.
Amount of Award: The approximate year 1 funding amount will be
$1,500,000 in Federal Fiscal Year (FYY) 2022 funds, subject to the
availability of funds. Funding amounts for years 2-5 will be set at
continuation.
Authority: This program is authorized under Public Law 108-25 (the
United States Leadership Against HIV AIDS, Tuberculosis and Malaria Act
of 2003).
Period of Performance: September 30, 2022 through September 29,
2027.
Dated: February 1, 2022.
Terrance Perry,
Chief Grants Management Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2022-02412 Filed 2-3-22; 8:45 am]
BILLING CODE 4163-18-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.